Skip to main content
Premium Trial:

Request an Annual Quote

Edit it Out

Five CRISPR researchers have launched a company, called Editas Medicine, that aims to develop that technology to edit genes that cause disease. The firm raised some $43 million in financing.

Feng Zhang, from the Massachusetts Institute of Technology and one of the new company's founders, tells Nature News that the company will likely start with diseases that arise due to one copy of a dysfunctional gene — putting that bad copy out of action would then allow the working copy of the gene to take over.

A main competitor, Nature News notes, is Sangamo, though that company uses zinc finger nucleases rather than CRISPR.

Both companies may eventually seek US Food and Drug Administration approval for their product, it adds. Nicholas Bishop, a biotechnology analyst at Cowen and Company, points out to Nature News that FDA has yet to approve a gene therapy product. He notes, though, that "the regulatory climate is thawing considerably."

The other founders of Editas Medicine are Harvard University's George Church, the University of California, Berkeley's Jennifer Doudna, Keith Joung at Harvard, and David Liu, also at Harvard.

The Scan

Genetic Ancestry of South America's Indigenous Mapuche Traced

Researchers in Current Biology analyzed genome-wide data from more than five dozen Mapuche individuals to better understand their genetic history.

Study Finds Variants Linked to Diverticular Disease, Presents Polygenic Score

A new study in Cell Genomics reports on more than 150 genetic variants associated with risk of diverticular disease.

Mild, Severe Psoriasis Marked by Different Molecular Features, Spatial Transcriptomic Analysis Finds

A spatial transcriptomics paper in Science Immunology finds differences in cell and signaling pathway activity between mild and severe psoriasis.

ChatGPT Does As Well As Humans Answering Genetics Questions, Study Finds

Researchers in the European Journal of Human Genetics had ChatGPT answer genetics-related questions, finding it was about 68 percent accurate, but sometimes gave different answers to the same question.